pfizer glp-1 agonist selects new drug for danuglipron | Pharmaceutical Business Review International posted on the topic Synapse - Global Drug Intelligence

Novo-Nordisk A/S, Eli Lilly And Company, Sanofi, AstraZeneca, Pfizer Inc., Amgen, Inc., and Innovent Biologics, Inc

While natural approaches to raising GLP-1 are not as potent as medications, they provide a drug-free approach to weight loss and healthy eating.

Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.

Research shows that nearly 90% of people with type 2 diabetes also struggle with their weight, and these medications solve both problems at once

GLP-1 receptor expression in renal pelvis, densely innervated by afferent renal nerve, was assessed by real-time PCR and western blot analysis